ARIAD Pharmaceuticals (ARIA) : Analyst Rating Update

ARIAD Pharmaceuticals (ARIA) : The consensus on ARIAD Pharmaceuticals (ARIA) based on 5 analyst recommendation on the company stock is 2.2, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.

ARIAD Pharmaceuticals (ARIA) : 5 Wall Street analysts covering ARIAD Pharmaceuticals (ARIA) believe that the average level the stock could reach for the short term is $10.4. The maximum price target given is $13 and the minimum target for short term is around $8, hence the standard deviation is calculated at $2.07.

ARIAD Pharmaceuticals (NASDAQ:ARIA): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.23 and $7.16 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $7.42. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.37, notching a gain of 1.52% for the day. The total traded volume was 2,121,760 . The stock had closed at $7.26 on the previous day.

Also, Major Brokerage house, Cowen & Company upgrades its ratings on ARIAD Pharmaceuticals (NASDAQ:ARIA). According to the latest information available, the shares are now rated Outperform by the analysts at the agency. Previously, the analysts had a Market Perform rating on the shares. The rating by the firm was issued on May 5, 2016. The company shares have dropped -3.97% from its 1 Year high price. On Aug 28, 2015, the shares registered one year high at $10.07 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $7.95 and the 200 Day Moving Average price is recorded at $6.58.

ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.